

In Collaboration With :



MYPACT

Multiple Myeloma Patient Centric Treatment

WORKSHOP

Date: 14 March 2020 (Saturday)

Venue: Sheraton Petaling Jaya

Time: 4.00pm to 7.00pm

Guest speaker: Prof. María-Victoria Mateos Manteca

Consultant Physician in the Haematology Department & Associate Professor of Medicine
University of Salamanca, Spain

Chaired by: Dr. Alan Teh

Time	Agenda
4:00- 4:10pm	Registration
4:10- 4:15pm	Welcome remarks by Chairperson
4:15- 5:15pm	Choice of initial treatment of multiple myeloma in the era of novel agents – when to use? by Prof. María-Victoria Mateos Manteca
5:15- 5:30pm	Tea break
5:30- 6:30pm	Patient profiling – treatment options (Case scenarios - group discussion) Facilitator: Prof. Mateos & Dr Alan Teh 1) Renal impairment 2) Fit 3) Frail 4) Multiple comorbidities
6:30- 7:00pm	Treatment approach and key parameters in treating Multiple Myeloma (Group discussion) Facilitator: Prof. Mateos & Dr Alan Teh
7:00pm	Dinner

For healthcare professionals only
CPD points will be awarded

An Educational Event Organized By :



PHARMACEUTICAL COMPANIES OF Johnson & Johnson



International Guest Speaker

Prof. María-Victoria Mateos Manteca

Prof. María-Victoria Mateos, MD, PhD, is a Consultant Physician in the Haematology Department and Associate Professor of Medicine at the University of Salamanca, Spain. She is the director of the Myeloma Program and coordinates the Clinical Trials Unit in Salamanca's University Hospital Haematology Department.

She serves as the coordinator of GEM (Spanish Myeloma Group), with direct involvement in the design and development of clinical trials. She has coordinated many clinical trials in elderly and smouldering MM patients that have profoundly influenced current options for treating these patient populations.

She is also a member of the IMWG (International MM Working Group), IMS (International MM Society), EHA and ASH. She has published over 200 papers in peer-reviewed international journals, some of which have become key references in the Multiple Myeloma field. She is the Associate Editor of myeloma in *Annals of Haematology* since 2011 and has acted as a reviewer for top journals such as *NEJM*, *Lancet* and *Lancet Oncology*. Among her invited presentations, she has recently contributed to the educational sessions of EHA 2012, ASH 2013, ASCO 2015, EHA 2016, ASCO and ASH 2017.

She has served on the EHA's Scientific Program Committee and Advisory Board since 2013 until 2017, and on the ASH Scientific Committee on plasma cell diseases in 2015-2017.

She is a Councilor on the EHA Board since 2015 for a four-year mandate, member of the Steering Committee for the Society of Haematologic Oncology (SOHO), member of the IMS board and member of the European School of Haematology (ESH) Scientific committee.

She has published over 200 original papers in international journals. Her areas of interest include multiple myeloma, the biology of plasma cells and the new drugs development.